Kornimate/medical-research-clean huggingface dataset:
non invasive imaging of abdominal aorta aneurysm hemodynamics and wall structure

Conditions: Aortic Aneurysm, Abdominal

Summary: the development of the abdominal aorta aneurysm is multifactorial. through use of magnetic resonance imaging without contrast, this study will look closely at flow, the stresses hereby induced, as well as signs of inflammation in the vessel wall.

the etiology of the abdominal aorta aneurysm is complex and multi-factorial. biomechanic and hemodynamic stress contributes to aneurysmal growth, and the relevance of inflammation is gaining in terms of pathological influence. the technical advances of imaging now enable one to utilize magnetic resonance in reconstructing aortal blood flow. newer post-imaging software then enables one to perform complex data analysis, wherein shear and wall-stress can be calculated. the goal of this study is to analyze the aneurysms of twenty patients. values will be obtained for shear and wall stress. additionally, the utilization of short tau wave inversion recovery (stir) sequences will be performed to evaluate the presence or absence of acute edema and inflammation of the region. it should also be noted that particular attention will be placed on the so-called "neck" of the aneurysm, where the aneurysm typically tapers into what is often regarded as normal aortic tissue. this region is important for both the placement of a surgical bypass prosthesis or a deployed stent graft.

Eligibility criteria:
inclusion criteria: * infrarenal abdominal aorta aneurysm (aaa) exclusion criteria: * lack of signed, informed consent * pacemaker or other implanted metal prostheses * claustrophobia * dementia * diabetes mellitus * thoracoabdominal aorta aneurysm, per crawford/safi criteria * ehlers-danlos, marfans, or other diagnosed connective tissue disease

Keywords: abdominal aortic aneurysm wall stress shear stress inflammation magnetic resonance imaging
intraoperative radiation therapy for resectable pancreatic cancer

Conditions: Resectable Pancreatic Cancer

Summary: this phase ii study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. the purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and iort is superior to that of surgical resection alone from the historical control. a total of 80 patients will be enrolled, and these patients will receive iort of 10 gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically diagnosed with adenocarcinoma of the pancreas or clinically diagnosed with imaging examinations or tumor markers * 20 years or older * performance status 0-2 based on eastern cooperative oncology group (ecog) * patients with surgically resectable or borderline resectable and advanced pancreatic cancer that can be resected after neoadjuvant chemotherapy * patients who voluntarily decided to participate in this clinical study and signed a written informed consent exclusion criteria: * history of previous abdominal irradiation. * when the treatment area is not included in the appropriate radiation field according to the judgment of the radiation oncologist or durgeon * distant metastasis * other systemic conditions that, under the judgment of the attending physician, would be difficult to undergo surgery or radiiotherapy

Keywords: pancreatic cancer intraoperative radiotherapy neoadjuvant chemotherapy
a computerized intervention for depression

Conditions: Depression

Summary: the primary purpose of this study is to examine how much change in depressive symptoms will be observed in persons who use an electronic problem solving treatment (imbpst) compared to a control group at pre-, mid-point, and post-test assessments.

an interactive multimedia computer-based treatment program was developed to provide an electronic version of problem solving therapy for depression (imbpst). the program was entirely automated and did not require the involvement of a live clinician, even though it was designed to provide a "virtual therapy" experience that feels more like interacting with a person than with a computer. the imbpst program was built to help individuals who did not have access to traditional therapy due the living conditions or individual preferences (e.g. rural, poor and persons desiring privacy or with significant time constraints). this computer-based treatment of depression offered several advantages. it can be used anywhere without a therapist present, and offered a standardized and consistent therapeutic approach. the aim of this study is to reduce symptoms of depression in subjects through the use of a new, electronic problem solving treatment (imbpst). adult participants with moderate to severe depression symptoms are randomly assigned to either treatment or a wait-list condition. the beck depression inventory-ii was used as the primary outcome measure

Eligibility criteria:
inclusion criteria: 1. be 18 years of age or older. 2. present symptoms from the following criteria based on the diagnostic \& statistical manual of mental disorders-iv-text revision (dsm-iv-tr): major depressive episode, mood disorder due to a general medical condition and/or adjustment disorder with depressed mood. 3. depression must be the primary diagnosis and not occur secondary to any another diagnosis such as post-traumatic stress disorder (ptsd), social phobia, or complicated bereavement, though comorbid diagnoses (e.g., anxiety disorders and ptsd) will not be exclusionary unless they are primary, except as specified below. 4. not receiving psychological treatment (e.g., face to face) at the time of the study. 5. not currently be receiving problem solving treatment in any other context. 6. not reporting/reported suicidal attempts in the year prior to their participation in the study. 7. be able to write and speak english according to rapid estimate of adult literacy in medicine (realm test scores) exclusion criteria: 1. current suicidal ideation, history of suicidal attempts or self-injurious behavior at any point during the protocol. 2. have been diagnosed with schizophrenia, bipolar i disorder, with psychosis, other disorder with psychotic symptoms, and/or brain injuries that includes loss of consciousness \> 15 minutes and / post-traumatic amnesia of any duration. 3. any history of treatment with anti-psychotic medication. 4. a felony conviction. 5. any current or recent (i.e. within the previous 6 months) substance abuse/dependence diagnosis (other than nicotine or caffeine). 6. current psychological treatment (e.g., face to face).
assessing continuous glucose monitor use in underserved primary care patients

Conditions: Type 2 Diabetes

Summary: continuous glucose monitoring (cgm) has demonstrated improved outcomes in both type 1 and type 2 diabetes populations in comparison to traditional methods; however, these devices have not been well studied in underserved adult patients (e.g., low-income, uninsured) who may face additional barriers to monitoring. furthermore, there is limited data exploring long-term (3- to 6- month) health care team-based management of these devices in the primary care setting. the purpose of this study is to further understand the benefits and barriers associated with cgm use in underserved populations with type 2 diabetes and improve their overall diabetes care.

continuous glucose monitoring (cgm) has demonstrated improved outcomes in both type 1 and type 2 diabetes populations in comparison to traditional methods; however, these devices have not been well studied in underserved adult patients (e.g., low-income, uninsured) who may face additional barriers to monitoring. furthermore, there is limited data exploring long-term (3- to 6- month) health care team-based management of these devices in the primary care setting. this study will evaluate the perceived and experienced benefits and barriers of continuous glucose monitor (cgm) and traditional glucometer use and identify diabetes related outcomes associated with cgm use relative to usual care with self-monitoring of blood glucose (smbg) in an underserved population. eligible adult (\>=19 years of age) patients at participating clinics with type 2 diabetes, a1c \>=9%, and concomitant insulin therapy and/or using two or more diabetes medications will be randomly enrolled to one of two groups: freestyle libre 2 cgm or traditional glucometer. pre- and post-surveys will be used to evaluate perceived and experienced benefits and barriers to cgm use and diabetes-related outcomes will be compared between the groups using face-to-face, telephonic, and/or digital avenues. the latter aim will replicate current processes of team-based diabetes care which is blood glucose management from a pharmacist under collaborative practice with the primary care physician. follow-up will also replicate these clinic processes throughout the 6-month period, including telephone calls and monthly in-clinic visits.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * a1c \>9% at recruitment * on/initiating insulin or on two or more diabetes medications exclusion criteria: * current use of an insulin pump * on dialysis * pregnant * implanted medical device (e.g., pace-maker, defibrillator) * intellectual or physical disabilities that may interfere with ability to properly use the continuous glucose monitor (cgm) * able to read english
study of alkotinib in patients with advanced non small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: to explore the dlt of zg0418 for patients with advanced alk+ or ros1+ nsclc and previously treated with chemotherapy or crizotinib, and to determine the mtd or the r2pd.

the study is a randomized, double-blind phase 1 trial including 2 sequential parts: single ascending dose(sad) part,multiple ascending dose(mad) part. sad and mad are dose-escalated tolerant study designing. the aims of the study as below: 1. evaluating the safety and tolerance of zg0418 in alk+ nsclc. 2. evaluating the fasting pharmacokinetic parameters of zg0418 in alk+ nsclcjaktinib. 3. evaluating the postprandial pharmacokinetic parameters of zg0418 in alk+ nsclc. 4. analysis the metabolites of zg0418

Eligibility criteria:
inclusion criteria: 1. advanced alk+ or ros1+ nsclc and previously treated with chemotherapy or crizotinib 2. eastern cooperative oncology group (ecog) performance status (ps) score of 0 to 2. 3. life expectancy of at least 12 weeks. 4. ability to swallow and retain oral medication. 5. adequate organ system function, defined as follows: 1. absolute neutrophil count (anc) ≥1.5 x 10\^9/l 2. platelets ≥75 x 10\^9/l 3. hemoglobin ≥9 g/dl (≥90 g/l) note that transfusions are allowed to meet the required hemoglobin level 4. total bilirubin ≤1.5 times the upper limit of normal (uln) 5. alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤2.5 x uln if no liver involvement or ≤5 x uln with liver involvement. 6. creatinine 1.5 x uln. 6. brain metastases allowed if asymptomatic at study baseline. 7. patients must have measurable disease per recist v. 1.1. exclusion criteria: 1. chemotherapy, radiation therapy, immunotherapy within 4 weeks. 2. presence of active gastrointestinal (gi) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications. 3. uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion.
a study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of chf6297 in healthy subjects and patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chf6297 is a potent and selective inhibitor of human map kinase p38 being developed as an anti-inflammatory agent for the treatment of inflammatory airways diseases. the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of chf6297 as dry powder formulation in healthy subjects and in copd patients. this study is the first administration in humans. the study will comprise four parts: part 1 will consist of two cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending dose (sad) of chf6297. part 2 will consist of four cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of multiple ascending dose (mad) of chf6297. part 3 will consist of one cohort of copd patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a repeat dose of chf6297 part 4 will consist of one cohort of healthy subjects to assess the anti-inflammatory effect of a repeat dose of chf6297 after lps challenge.


Eligibility criteria:
inclusion criteria: part 1, part 2, part 4 (healthy subjects): * male subjects aged 18-55 years; * non smokers * lung function above 80% of predicted normal value * healthy subjects based on medical evaluation including medical history, physical examination, laboratory tests and cardiac testing * ability to produce an adequate induced sputum sample (study part 4 only) part 3 (copd patients): * males and females aged 40-75 years * current or past smokers * stable patients with a post-bronchodilator fev1 between 40 and 80% of predicted normal value and fev1/fvc ratio \<0.7 * ability to produce a spontaneous and an adequate induced sputum sample exclusion criteria: parts 1,2, 4 (healthy subjects): * any clinically relevant abnormalities and/or uncontrolled diseases * abnormal laboratory values * recent respiratory tract infection * hypersensitivity to the drug or excipients * positive serology results * positive cotinine, alcohol, drug of abuse tests part 3 (copd patients): * females of childbearing potential * history of asthma * unstable concomitant diseases * abnormal relevant holter ecg parameters * recent acute exacerbations of copd or respiratory tract infection * hypersensitivity to the drug or excipients * positive serology results
study of ammoxetine hydrochloride enteric-coated tablets in healthy subjects

Conditions: Depression

Summary: this study evaluates the safety, tolerability and pharmacokinetics of ammoxetine hydrochloride enteric-coated tablets in chinese heathy subjects. part of the participants will receive ammoxetine hydrochloride enteric-coated tablets, while the other part will receive placebo.


Eligibility criteria:
inclusion criteria: * males and females age 18-45 years * body weight ≥ 45kg (female) or 50kg (male), 18 ≤ bmi ≤ 26 * vital signs, physical examinations and laboratory tests and other tests prove participants are healthy * sign the informed consent form voluntarily and cooperate voluntarily to complete the test exclusion criteria: * allergens (allergic to 2 or more drugs, food or pollen) * comorbid illness (mental illness, liver and kidney disease, gastrointestinal diseases, nervous system disease, or other systemic diseases) * have clinically significant abnormal screening laboratory values. * systolic pressure \> 140mmhg or diastolic \> 90 mmhg * postural hypotension (systolic blood pressure drop by 20mmhg or diastolic blood pressure drop by 10mmhg after standing position) * the qtc period ≥ 450ms (male) or 470ms (female) or has a history of qtc extension * smoking or alcohol consumption (14 units per week in the previous 4 weeks : 1 unit = beer 285ml, or 25ml of spirits, or 150 ml of wine; daily smoking ≥ 5) or abusing in past year of drug and other substance * have donated blood \> 400 ml within 8 weeks prior to screening * participated in other clinical trials within 3 months prior to screening * intaked too much caffeinated beverage or food within 4 weeks prior to screening. such as: coffee, tea, chocolate, cola, red bull (no more than 6 units per day). 1 unit of caffeine = 1 cup of coffee (177.4 ml) = 2 pots of cola (354.9 ml) = 1 cup of tea (354.9 ml) = 1/2 cup energy drink = 85g chocolate * have taken drugs that changed liver enzyme activity, such as dexamethasone, ketoconazole, rifampicin and omeprazole, were used within 4 weeks prior to screening * have taken prescription drugs and otc (except for the occasional use of acetaminophen and nasal sprays), herbs vitamins or minerals within 4 weeks prior to screening. the interval from prior treatment to screening should be at least 5 half-lives metablism which subjected to the longer half-life * using any psychotropic drug or psychoactive substance * women were screened for positive blood pregnancy * the subjects and their partners were not willing to take contraceptives during trial and six months after the study * have a donor plan recently * have participated in this trial * the researchers believe that anyone who is unfit to participate in this test will be involved
an attempt to reduce community-acquired methicillin-resistant staphylococcus aureus (mrsa) infection in soldiers

Conditions: Community-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis

Summary: the main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant staphylococcus aureus (mrsa) will reduce infections in them and their cohort of fellow soldiers.

community-acquired mrsa infections are increasingly common in the community and in particular among certain groups of which soldiers are one. many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate ca-mrsa in those who are colonized with the pathogen. the two main purposes of the study are: to determine if selective ca-mrsa eradication in subjects reduces infections in the ca-mrsa colonized individual; and to determine if selective ca-mrsa eradication in subjects reduces infections in the study cohort. other information concerning ca-mrsa includes: prevalence, risk factors, and virulence data. the population will be soldiers enrolled in the combat medic training class at ft. sam houston. we will enroll approximately 3000 soldiers over a two year period. after informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. the follow-up period will be 16 weeks. for those with ca-mrsa in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.

Eligibility criteria:
inclusion criteria:soldiers enrolled into the combat medic course at ft. sam houston, tx. - exclusion criteria: allergy to mupirocin. -

Keywords: methicillin-resistant staphylococcus aureus staphylococcus aureus mrsa ca-mrsa
effect of systemic isotretinoin on serum irisin level in acne vulgaris patients

Conditions: Acne Vulgaris

Summary: acne vulgaris is a chronic inflammatory skin disease affecting the pilosebaceous unit. it is clinically characterized by comedones, papules, pustules, nodules, cysts and scarring on the face and trunk. the severity of the disease ranges from mild comedonal acne to severe nodulocystic acne which can be permanently disfiguring.in addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.in addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.

the prevalence of self-reported acne and clinically confirmed acne was 34.69% and 24.39%, respectively. females reported acne more frequently than males did (39.13% ).the prevalence of clinically confirmed acne was higher among females (28.64%) than males . its pathogenesis results from androgen-induced increased sebum production, altered keratinization, inflammation of infundibular epithelium and bacterial colonisation of hair follicles by propionibacterium acne there are several treatment modalities for acne vulgaris including topical like topical antibiotics, topical benzoyl peroxide, topical azelaic acid and topical retinoids. systemic therapy like antibiotics, hormonal therapy and isotretinoin . adipokines may have a role in the pathogenesis of acne vulgaris and are associated with acne severity. irisin, a hormone -like myokine, is one of the adipokines with anti- inflammatory and anti-oxidant effects there is limited evidence for physical modalities (e.g., laser therapy, light therapy, chemical peels) and complementary therapies (e.g., purified bee venom, low-glycemic-load diet, tea tree oil) . isotretinoin (13-cis retinoic acid) is the most potent known inhibitor of sebum production. the multiple modes of action for isotretinoin includs suppression of sebaceous gland activity, normalization of the pattern of keratinization within the sebaceous gland follicle, inhibition of inflammation and reduction of growth of propionibacterium acne .

Eligibility criteria:
inclusion criteria: * cases with moderate and severe acne. * clinical diagnosis of acne disease * patient not receive any treatment for acne vulgaris at least six months duration. exclusion criteria: 1 pregnant and lactating women. 2. history of chronic liver disease . 3. cardiovascular disorders . 4. renal disease . 5. hyperlipidemia . 6. depression or mental illness. 7. insulin dependent diabetes 8 thyroid disease. 9 osteoporosis or low bone mineral density . 10 intestinal disorders such as inflammatory bowel disease or ulcerative colitis
urdu version of modified oswestry low back pain scale; a reliability and validity study

Conditions: Lumbar Radiculopathy

Summary: the ultimate goal of this study is to interpret modified oswestry low back pain scale into urdu and analyse its reliability and validity in the population of pakistan lumber radiculopathy patients. examine its correlation with quebec back pain disability scale and the visual analogue scale, as well as the roland-morris disability questionnaire.

as per preceding commendation, modified oswestry low back pain scale will be translated into urdu language from its english version and adapted culturally in pakistan. 100 individuals will be selected on the basis of convenience sampling with clinical characteristics. the patient will answer the questionnaire package that included the urdu version modified oswestry low back pain scale, quebec back pain disability scale, roland-morris disability questionnaire and visual analogue scale on the same day, with a 30-minute delay between the first and second application. observer-1 will be conducting a third assessment after 7 days for intra-observer evaluation. statistical package of social sciences version 24 will be used to enter and evaluate the data. internal consistency will be measured using the cronbach alpha value. to evaluated test-retest reliability, an intraclass correlation coefficient will be employed. the modified oswestry low back pain scale will be evaluated for content validity, construct validity, criterion validity, and responsiveness.

Eligibility criteria:
inclusion criteria: * both genders, between the ages of 18 to 65, * individuals who could read and speak urdu as a first language * people who have been diagnosed with lumbar radiculopathy by a physician or neurosurgeon, * low back pain in the lower extremities with or without radicular pain. exclusion criteria: * female patients who were pregnant * patients with a mental health history, cancer, or neurological problems * acute low back pain is a frequent disease (included recent thoraco-lumbar trauma), * psychiatric and behavior issues, systemic disease (tumors and rheumatological diseases), and central or peripheral neurological problems * patients who had recently had a cerebrovascular accident or a myocardial infarction were also ruled out.

Keywords: modified oswestry low back pain scale urdu version reliability validity lumbar radiculopathy low back pain